Highnoon Laboratories Delivers Strong Financial Performance for 2025
Highnoon Laboratories Limited has reported a strong financial performance for the year ended December 31, 2025, with the company’s financial statements showing continued growth in profitability and earnings per share.
According to the company’s announcement, the Board of Directors, in its meeting held on April 6, 2026, recommended a 500% cash dividend, while no bonus shares or right shares were proposed. The company also announced that its Annual General Meeting would be held on April 30, 2026, at its registered office in Lahore.
Profitability Shows Positive Momentum
The financial statements indicate that Highnoon Laboratories maintained a solid level of profitability during the year. The standalone financial results show profit before tax of approximately Rs6.58 billion, compared with approximately Rs4.46 billion in the previous year. Profit after tax stood at around Rs4.12 billion, while earnings per share increased to Rs77.75, compared with Rs61.41 previously.
The consolidated results also reflect a strong performance. Consolidated earnings per share increased to approximately Rs77.92, compared with Rs63.95 in the previous year. The consolidated financial statements also show profit before tax of approximately Rs6.60 billion.
Financial Position Remains Significant
The company’s balance sheet shows a substantial asset base, supported by inventories, trade receivables, cash and bank balances, and other current assets. The consolidated statement of financial position also records total assets of approximately Rs19.44 billion at the end of 2025.
The financial statements further show that Highnoon Laboratories generated cash from operating activities during the year, while continuing to invest in property, plant and equipment and other investment activities. The cash-flow statement records net cash generated from operating activities of approximately Rs1.82 billion on a consolidated basis.
500% Cash Dividend Recommended
One of the key highlights for shareholders is the Board’s recommendation of a 500% cash dividend for the year ended December 31, 2025. The announcement states that no bonus shares, right shares, or other entitlement/corporate action were recommended.
The dividend recommendation is subject to the applicable corporate approval process. The company has also notified shareholders about the upcoming Annual General Meeting, where the financial results and other relevant matters will be considered.
Outlook
Highnoon Laboratories’ 2025 financial statements point to a year of improved earnings, higher earnings per share and continued operating cash generation. The combination of stronger profitability and the proposed cash dividend will be closely watched by shareholders and market participants.
The company’s results provide an overview of its financial position and performance for the year ended December 31, 2025, while the proposed dividend represents an important component of the company’s shareholder distribution for the period.
